The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | What’s new in myeloproliferative neoplasms?
Jean-Jacques Kiladjian, MD, PhD from Saint-Louis Hospital & Paris Diderot University, Paris, France discusses a selection of topics covered during the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Kiladjian outlines presentations on myeloproliferative neoplasms, specifically essential thrombocythemia (ET) and the PT-1 trial, and polycythemia vera (PV). In talks regarding treatment of PV it was discussed how ruxolitinib could lessen the JAK2 mutant allele burden.
